The burden of non-radiographic axial spondyloarthritis

Pathophysiology and treatment of rheumatic disease

CHANGE IN SACROILIAC JOINT STRUCTURAL RADIOGRAPHIC DAMAGE AFTER TWO YEARS OF ETANERCEPT THERAPY IN COMPARISON TO A CONTEMPORARY CONTROL COHORT IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

Pathophysiology and treatment of rheumatic disease

Sustained Remission of Inflammation Is Associated with Reduced Structural Damage on SI Joint MRI in Patients with Early Axial Spa: Evidence to Support the Concept of Treat-to-Target

Pathophysiology and treatment of rheumatic disease

Detection of Structural Lesions on T1 Weighted MRI Versus Radiography of the Sacroiliac Joints in Early Axial Spa: 2-Year Data

Pathophysiology and treatment of rheumatic disease

CHANGE IN MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINT AFTER TWO YEARS OF ETANERCEPT THERAPY IN COMPARISON TO A CONTEMPORARY CONTROL COHORT

Pathophysiology and treatment of rheumatic disease

Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Pathophysiology and treatment of rheumatic disease

In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.: Anti-myeloma activity of amplified gamma delta T cells

International audienceT-cell-mediated immunotherapy is a promising therapeutic option for multiple myeloma (MM). Gamma-delta T cells (gammadelta T cells) recognize phosphoantigens and display strong anti-tumour cytotoxicity. The synthetic agonist Phosphostim (bromohydrin pyrophosphate, BrHPP) has been shown to selectively activate Vgamma9Vdelta2 T cells. This study aimed to evaluate the expansion capacity and anti-myeloma cell cytotoxicity of circulating gammadelta T cells from MM patients at different time points throughout the disease, using Phosphostim and interleukin 2 (IL-2). Circulating gammadelta T cell counts in patients with newly diagnosed MM or in relapse did not differ from those in healthy donors. A 14-d culture of peripheral blood mononuclear cells with Phosphostim and IL-2 triggered a 100-fold expansion of gammadelta T cells in 78% of newly diagnosed patients. gammadelta T cells harvested at the time of haematopoietic progenitor collection or in relapsing patients expanded less efficiently. Expanded gammadelta T cells killed 13/14 myeloma cell lines as well as primary myeloma cells, but not normal CD34 cells. Their killing efficiency was not affected by 2-d IL-2 starvation. This study demonstrated the ability of Phosphostim and IL-2 to expand gammadelta T cells from MM patients, and the efficient and stable killing of human myeloma cells by gd T cells